Company Filing History:
Years Active: 1988-1990
Title: **James W. Freeman: Pioneering Cancer Detection Innovations**
Introduction
James W. Freeman, a notable inventor based in Houston, TX, has made significant contributions to the field of cancer detection. With two patents to his name, his work focuses on innovative methodologies to identify human cancer cells through unique antibody applications. His research aims to enhance cancer diagnosis, providing crucial advancements in medical science.
Latest Patents
Freeman's latest patents include groundbreaking approaches to detecting human cancer cells. His first patent details a method where tumor nucleoli are treated with polyclonal antisera to normal human tissue nucleoli, effectively blocking common determinants found in both tumor and normal tissue nucleoli. This innovative process involved immunizing mice with these immune complexes, ultimately leading to the development of a monoclonal antibody known as FB2. This antibody targets a novel nucleolar proliferation-associated antigen, showcasing its potential in cancer cell detection.
The second patent focuses on the identification of specific common nucleolar antigens found in various human malignant tumor specimens. These antigens are isolated, extracted, and purified, allowing for the cultivation of monoclonal antibodies specific to one of these nucleolar antigens, referred to as p145. These antibodies are harvested from mouse ascites or culture supernatants and play a crucial role in detecting human cancer.
Career Highlights
Freeman's affiliation with the Biosciences Corporation of Texas has provided him with a platform to innovate and develop his research further. His dedication to advancing cancer diagnosis through innovative antibody technology demonstrates his commitment to improving healthcare outcomes. His two patents attest to his inventive spirit and the impact of his work on cancer detection practices.
Collaborations
In his pursuit of effective cancer detection methods, Freeman has collaborated with notable coworkers such as Harris Busch and Rose K. Busch. Together, they have contributed to various research initiatives aimed at enhancing the understanding and detection of human cancer.
Conclusion
James W. Freeman’s work in the domain of cancer detection stands as a testament to the power of innovation in addressing significant medical challenges. His patents reflect a proactive approach to utilizing antibodies for the identification of cancer cells, paving the way for improved diagnostic techniques. As part of the scientific community, Freeman’s contributions will undoubtedly continue to influence advancements in cancer research and treatment methodologies.